Skip to content
06/16/2026
  • Voce di menu
  • Voce di menu
  • Voce di menu
  • Voce di menu
  • Our Profile on PRLog
Merlintrader Trading Pub

Merlintrader Trading Pub

Biotech catalyst news and analysis. FDA PDUFA tracker

DISCLAIMER — Educational content only. Not financial advice. Stocks can be volatile and may cause capital loss.
Read Disclaimer
Primary Menu
  • Merlintrader
    • About Merlintrader
    • Merlintrader Blog
    • Daily Briefing
    • Daily Watchlist
    • Discord
    • Latest News
    • Small & Medium Caps
    • CHARTSWATCHER 10% OFF !
    • Disclaimer
  • Cannabis Stocks Hub 2026
    • Cannabis Stocks HUB 2026: A Possible Reset for a Broken Sector $MSOS, $TLRY, $CGC, $CRON, $ACB
    • Tilray Brands (Nasdaq: $TLRY): Cannabis, Beverage and Medical Cannabis Stock Hub
  • Space, Defense & AI Hub 2026
    • BlackSky Technology Inc. (NYSE: $BKSY) Stock Hub
    • BigBear.ai Holdings (NYSE: $BBAI)
    • Castellum, Inc. (NYSE American: $CTM) Stock Hub
    • Intuitive Machines (Nasdaq: $LUNR) Stock Hub
    • Ondas Holdings (NASDAQ: $ONDS) Stock Hub
    • Palladyne AI Corp. (Nasdaq: $PDYN) Stock Hub
    • Planet Labs PBC (NYSE: $PL)
    • POET Technologies (NASDAQ: $POET): Company Story,
    • Red Cat Holdings (NASDAQ: $RCAT)
    • Redwire Corporation (NYSE: $RDW) Stock Hub
    • Rocket Lab Corporation (Nasdaq: $RKLB) Stock Hub
    • Satellogic Inc. (Nasdaq: $SATL)
  • Biotech Stocks Hub
    • ADMA Biologics (Nasdaq: $ADMA)
    • Agios Pharmaceuticals (Nasdaq: $AGIO) Stock Hub
    • Alpha Tau Medical Ltd. (Nasdaq: $DRTS)
    • Altimmune Inc. (Nasdaq: $ALT )
    • Aquestive Therapeutics (Nasdaq: $AQST Stock Hub.
    • Ardelyx, Inc. (Nasdaq: $ARDX) Stock Hub
    • BioCryst Pharmaceuticals (Nasdaq: $BCRX) Stock Hub
    • Capricor Therapeutics (Nasdaq: $CAPR) Stock Hub
    • Corcept Therapeutics $CORT Stock Hub
    • CorMedix Therapeutics (Nasdaq: $CRMD) Stock Hub
    • Cytokinetics, Incorporated (Nasdaq: $CYTK)
    • Fate Therapeutics (Nasdaq: $FATE): Stock Hub
    • Geron Corporation (Nasdaq: $GERN) Stock Hub
    • ImmunityBio, Inc. (Nasdaq: $IBRX) Stock Hub
    • Iovance Biotherapeutics (Nasdaq: $IOVA)
    • MannKind Corporation (Nasdaq: $MNKD) Stock Hub
    • Microbot Medical Inc. (Nasdaq: $MBOT) Stock Hub
    • Moleculin Biotech (Nasdaq: $MBRX) Stock Hub
    • Novavax, Inc. (Nasdaq: $NVAX) Stock Hub
    • NRx Pharmaceuticals (Nasdaq: $NRXP) Stock Hub
    • Ocugen, Inc. (Nasdaq: $OCGN) Stock Hub
    • Ocular Therapeutix (Nasdaq: $OCUL) Stock Hub
    • Omeros Corporation (Nasdaq: $OMER): Stock Hub
    • Outlook Therapeutics (Nasdaq: $OTLK): Stock Hub
    • Protalix BioTherapeutics (NYSE American: $PLX) Stock Hub
    • SeaStar Medical Holding Corporation (Nasdaq: $ICU) Stock Hub
    • SELLAS Life Sciences Group (Nasdaq: $SLS) Stock Hub.
    • Summit Therapeutics (Nasdaq: $SMMT) Stock Hub
    • Travere Therapeutics (Nasdaq: $TVTX)
    • Viridian Therapeutics (Nasdaq: $VRDN)
  • FREE CATALYST CALENDAR
    • Catalyst Total Tracker
  • Merlintrader Travel Pub

Home - Intraday - JFBR Jeffs Brands Ltd

  • Intraday
  • Small Caps Trending

JFBR Jeffs Brands Ltd

Jeffs’ Brands Ltd is a tiny Israeli micro-cap originally built around a data-driven Amazon FBA portfolio. That legacy business is still there: roughly $13.7M revenue in FY2024 against a net loss of about $7.8M, with a very small equity value and high operating leverage. The last twelve months have been brutal for long-term holders, with a price trajectory closer to a ski slope than a growth story.
3 views
Jeffs’ Brands (JFBR) – KeepZone AI x STI Daily Hit | Merlintrader trading Blog
DAILY HIT – SMALL CAPS / SECURITY & AI

Jeffs’ Brands (JFBR) – KeepZone AI x STI: Amazon micro-cap trying to become a mini “security one-stop shop”

Distribuzione non esclusiva delle tecnologie STI (ispezione veicoli e rilevazione esplosivi) in Canada e Messico: perché il mercato ha sparato JFBR in alto e cosa resta se togli la narrativa.

Ticker: JFBR (Nasdaq) Sector: E-commerce → Homeland Security / AI pivot KeepZone AI x STI deal – Jan 16, 2026
JFBR – daily chart (Finviz) click = full Finviz with affiliate
Jeffs’ Brands (JFBR) – daily chart from Finviz
Last price (approx.)
$0.56
24h move ≈ −5.4% – high volatility
Market cap
~$1.8M
Micro-float, thin book
52-week range*
$0.53 – $44.37
split-adjusted range; current price ≈−99% vs 52-week high
FY2024 revenue / net income
$13.7M / −$7.8M
asset-light, ma ancora in forte perdita
Merlintrader Health Score (12–18m)
Composite 1–5 (cash, catalyst, dilution, liquidity, execution)
2.1 / 5 – fragile micro-cap pivot (weak balance sheet & dilution risk, positive but early-stage security story)
Analyst Target Range (6M)
Price targets from covering analysts
No recent 6-month analyst price targets reported for JFBR on major data providers (Zacks, etc.). For now, the “range” is entirely market-driven rather than anchored to formal Street coverage.

1. What kind of name JFBR is today

Jeffs’ Brands Ltd is a tiny Israeli micro-cap originally built around a data-driven Amazon FBA portfolio. That legacy business is still there: roughly $13.7M revenue in FY2024 against a net loss of about $7.8M, with a very small equity value and high operating leverage. The last twelve months have been brutal for long-term holders, with a price trajectory closer to a ski slope than a growth story.

Over the last few months, however, management has started to push a very different narrative: Jeffs’ Brands as a sort of mini-holding that uses its wholly-owned subsidiary KeepZone AI to enter the global homeland security market with AI-driven solutions. Scanary (AI radar), Zorronet (autonomous SOC), RT LTA Systems (aerostat surveillance) and now STI (under-vehicle inspection & explosives detection) are all pieces of that new puzzle.

2. What exactly today’s STI deal says

The January 16, 2026 GlobeNewswire release states that KeepZone AI has entered into a non-exclusive distribution agreement with STI Ltd., an Israeli security technology company specialized in under-vehicle inspection systems (UVIS) and explosives detection devices. KeepZone will cover Canada and Mexico, with the option to obtain temporary exclusivity windows (up to six months) for specific approved customers – essentially “give us some time to work this account alone before you open it to more distributors”.

The products covered range from fixed and mobile UVIS platforms to portable and stationary explosives detectors, plus other advanced threat-detection tools that STI already sells globally. The obvious targets are border-security agencies and critical-infrastructure operators: the PR explicitly name-drops the Canadian Department of National Defence, the RCMP, Mexico’s Secretaría de la Defensa Nacional and the Guardia Nacional as example customers.

From management’s angle, the key message is not “we invented a new sensor” but “we are becoming a one-stop shop for integrated security solutions”. STI is one more tile in a mosaic that already includes AI radar (Scanary), aerostat ISR platforms (RT LTA) and autonomous security operations (Zorronet).

3. Is this really a one-off PR? The broader KeepZone build-out

If you line up the last month of GlobeNewswire and Nasdaq releases, the pattern is very clear: Jeffs’ Brands is actively repositioning itself away from pure Amazon retail and deeper into homeland security. The Scanary deal opened the AI radar door, RT LTA brought aerial ISR, Zorronet brought security-operations orchestration, and now STI adds under-vehicle and explosives detection.

Importantly, all these moves are structured as representation / distribution agreements or similar – asset-light, low CAPEX, but also low immediate visibility on revenue and margins. KeepZone acts as an integrator and channel partner, not as the IP owner. From a run-up trader’s point of view, that matters: it makes the “story” much easier to scale on paper, but the actual P&L impact will depend entirely on whether big-ticket contracts follow.

4. Why the stock went ballistic on the news

In today’s session, JFBR behaved exactly like you would expect from a micro-float name with a hot narrative attached: the combination of “AI” + “homeland security” + “Canada & Mexico government targets” was enough to send the stock into a violent spike, with intraday gains reported in the triple-digit range and turnover many times above its usual volume.

On paper, though, nothing in this specific PR changes the company’s hard numbers overnight. There is no dollar value attached to the STI agreement, no backlog figure, no margin guidance. All we know is that KeepZone can now sell another set of products in two new geos, under a structure that remains non-exclusive at the master level.

The simplest interpretation is that the market is pricing optionality, not fundamentals: the option that one of these security deals eventually lands a large contract, validating the entire pivot and re-rating JFBR from tiny Amazon seller to niche defence integrator.

5. Run-up lens: where is the real “catalyst”?

In a pure run-up framework, today’s PR is not a binary event but a story-builder. There is no fixed date like a PDUFA or a Phase 3 readout. What you have instead is a series of potential triggers:

  • a first named contract in Canada or Mexico, with disclosed value and duration;
  • evidence that KeepZone is acting as a real integrator (combining Scanary + RT LTA + STI, etc.) rather than a simple reseller;
  • any indication that the legacy Amazon business is being gradually monetised or de-emphasised to reduce the cash burn.

Until something like that shows up in filings or more detailed PRs, the STI announcement stays in the “high-beta narrative” bucket: it can drive brutal gaps and short squeezes, but there is no fundamental anchor yet.

6. Risk map – why the Health Score is only 2.1 / 5

The 2.1 / 5 Merlintrader Health Score is not a judgement on whether the stock “deserves” to go up or down but a 12–18-month fragility snapshot built on five weighted pillars:

  • Balance sheet / runway (30%) – double-digit-million revenue but high losses, tiny market cap, strong dependence on execution. Score: weak.
  • Catalysts & concentration (30%) – several corporate catalysts (Scanary, RT LTA, STI, Fort Technology listing) but all early-stage and execution-heavy. Score: mid-range.
  • Dilution / capital structure (20%) – micro-cap with volatile share price, history of drawdowns and clear probability that more equity will be needed if the pivot doesn’t begin to pay off. Score: weak.
  • Liquidity (10%) – generally thin order book with occasional volume explosions on news. Liquidity is there on “event days” but not structurally. Score: mid-low.
  • Execution & governance (10%) – management is clearly pushing a strategic shift and has lined up multiple partnerships, but there is still no track record of successful large contracts in this new vertical. Score: mid-low.

Combine those weights and you land around 2.1 / 5 – a name that can absolutely produce spectacular spikes on news, but with a structural risk profile that remains very high if you extend the time horizon.

7. What to actually watch from here

Stripped of the hype, the next few checkpoints that really matter for the JFBR / KeepZone story are quite concrete:

  • any PR that moves from “distribution agreement” to “signed contract worth X over Y years”, especially with the government names hinted in today’s release;
  • SEC filings or investor decks that break out KeepZone’s revenue and margin profile instead of mixing everything into the e-commerce base;
  • clarity on how much of the Amazon business is being de-risked or divested over time, given how exposed it is to platform policy and margin compression.

In other words: from a catalyst-trading angle the story is alive and kicking, but the truly important lines will be in the next 8-K and in the details of any real contract announcement, not in the headline alone.

Key primary sources & data

  • GlobeNewswire – Jeffs’ Brands / KeepZone AI x STI distribution agreement (Jan 16, 2026) Official PR
  • Jeffs’ Brands – KeepZone AI RT LTA aerostat representation agreement (prior PRs) Finviz news stream
  • Financials & quote (FY2024 revenue, net income, market cap, last price, 52-week range) Yahoo Finance · Nasdaq · Investing.com · TradingView · Finviz quote
  • Analyst coverage snapshot (no active targets) Zacks – JFBR price target page
Legal / educational note. This Daily Hit is an informational overview based solely on official company releases, financial filings and reputable market data sources. It is not investment advice, does not contain buy/sell recommendations and must not be read as a solicitation to invest. Micro-cap names like JFBR can be extremely volatile and illiquid; anyone considering trading them should independently review primary documents (SEC filings, audited reports, full press releases) and, where needed, consult a licensed financial professional in their jurisdiction.

1. Che tipo di titolo è JFBR oggi

Jeffs’ Brands Ltd nasce come micro-cap israeliana costruita su un portafoglio Amazon FBA “data-driven”. Quel business c’è ancora: circa 13,7 milioni di dollari di ricavi nel 2024 a fronte di una perdita netta intorno ai 7,8 milioni, con capitalizzazione minuscola e leva operativa elevata. Negli ultimi dodici mesi il grafico ha avuto più la forma di una pista da sci che di una storia di crescita.

Negli ultimi mesi però il management sta spingendo una narrativa molto diversa: Jeffs’ Brands come mini-holding che, tramite la controllata al 100% KeepZone AI, vuole entrare nel mondo homeland security con soluzioni basate su intelligenza artificiale. I tasselli già annunciati sono diversi: Scanary (radar AI), Zorronet (autonomous SOC), RT LTA Systems (aerostati ISR) e ora STI (ispezione veicoli e rilevazione esplosivi).

2. Cosa dice davvero il deal con STI di oggi

Il comunicato GlobeNewswire del 16 gennaio 2026 spiega che KeepZone AI ha firmato un accordo di distribuzione non esclusivo con STI Ltd., società israeliana specializzata in sistemi di ispezione sotto-veicolo (UVIS) e rilevatori di esplosivi. KeepZone coprirà Canada e Messico, con la possibilità di avere finestre di esclusiva temporanea (fino a sei mesi) su clienti specifici approvati – in pratica: “per un certo periodo lasciateci lavorare questo cliente senza altri distributori”.

I prodotti coperti vanno da piattaforme UVIS fisse e mobili a rilevatori di esplosivi portatili e da tavolo, più altre soluzioni di advanced threat detection che STI già vende a livello globale. I target naturali sono autorità di frontiera e operatori di infrastrutture critiche: nel PR vengono citati esplicitamente il Department of National Defence canadese, la Royal Canadian Mounted Police, la Secretaría de la Defensa Nacional e la Guardia Nacional in Messico.

Dal punto di vista del management il messaggio chiave non è “abbiamo inventato un nuovo sensore” ma “stiamo diventando un one-stop shop di soluzioni integrate di sicurezza”. STI è un tassello in più in un mosaico che include già radar AI (Scanary), piattaforme aerostatiche ISR (RT LTA) e centri operativi di sicurezza autonomi (Zorronet).

3. Non è un PR isolato: il percorso KeepZone

Se metti in fila l’ultimo mese di comunicati GlobeNewswire / Nasdaq vedi chiaramente la traiettoria: Jeffs’ Brands sta spostando il baricentro dal puro retail Amazon verso il mondo homeland security. L’accordo con Scanary ha aperto la porta al radar AI, quello con RT LTA agli aerostati di sorveglianza, Zorronet porta l’orchestrazione dei sistemi di sicurezza, STI aggiunge ispezione veicoli e rilevazione esplosivi.

Tutte queste mosse però sono strutturate come accordi di distribuzione / rappresentanza: modello asset-light con CAPEX basso, ma anche visibilità immediata limitata su ricavi e margini. KeepZone agisce da integratore e canale commerciale, non è proprietaria dell’IP. Per un’ottica da run-up trader questo conta: la “storia” sulla carta scala facile, ma l’impatto sul conto economico dipende al 100% dall’arrivo di contratti importanti.

4. Perché il titolo è esploso su questa news

Nella seduta di oggi JFBR si è comportata esattamente come ti aspetti da una micro-cap con float sottile e narrativa calda: combinazione di “AI” + “sicurezza dei confini” + “Canada e Messico” e il risultato è stato uno spike violento, con guadagni intraday a tre cifre e volumi multipli rispetto alla media.

Sulla carta però nulla in questo specifico comunicato cambia subito i numeri duri: non c’è un valore economico indicato, non ci sono dati di backlog, nessuna guidance di margine. Sappiamo soltanto che KeepZone può proporre un nuovo set di prodotti in due nuove aree, con un accordo che rimane non esclusivo a livello master.

L’interpretazione più semplice è che il mercato stia prezzando opzionalità, non fondamentali: l’opzione che uno di questi deal si trasformi in un contratto grosso, validando il pivot e ri-prezzando JFBR da micro venditore Amazon a piccolo integratore difesa/sicurezza.

5. Lente “run-up”: dov’è il vero catalyst?

In ottica run-up, il comunicato STI non è un evento binario ma un mattoncino di storia. Non c’è una data fissa tipo PDUFA o readout di Fase 3; hai invece una serie di trigger potenziali:

  • un primo contratto nominato in Canada o Messico con valore e durata espliciti;
  • evidenza che KeepZone agisca da integratore vero (Scanary + RT LTA + STI, ecc.) e non solo da rivenditore;
  • segnali che il business Amazon venga progressivamente monetizzato o ridotto per limitare l’impatto della cassa bruciata.

Fino a quando qualcosa del genere non appare in filing o in PR più dettagliati, l’annuncio STI resta nel cassetto “high-beta narrativa”: perfetto per movimenti violenti a breve, poco ancoraggio se guardi ai fondamentali.

6. Mappa rischi – perché l’Health Score è solo 2,1 / 5

Il punteggio 2,1 / 5 del Merlintrader Health Score non è un verdetto pro/contro il titolo, ma una fotografia di fragilità 12–18 mesi basata su cinque pilastri ponderati:

  • Bilancio / runway (30%) – ricavi in crescita ma perdite importanti, capitalizzazione minima, forte dipendenza dalla capacità di eseguire il pivot. Punteggio: debole.
  • Catalyst & concentrazione (30%) – vari catalyst corporate (Scanary, RT LTA, STI, Fort Technology) ma tutti in fase iniziale e molto legati all’esecuzione. Punteggio: medio.
  • Dilution / struttura del capitale (20%) – micro-cap con storia di drawdown pesanti e, realisticamente, probabilità non trascurabile di ulteriori aumenti di capitale se il pivot non porta cassa. Punteggio: debole.
  • Liquidità (10%) – libro ordini generalmente sottile, con volumi che esplodono solo a ridosso delle news. Punteggio: medio-basso.
  • Execution & governance (10%) – il management sta costruendo la storia in modo coerente (più accordi in pochi mesi) ma non ha ancora una track record consolidata di grandi contratti in questo settore. Punteggio: medio-basso.

Mettendo insieme i pesi arrivi a circa 2,1 / 5: titolo capace di produrre spike spettacolari sulle news, ma con un profilo di rischio che resta molto alto appena sposti l’orizzonte un po’ più in là.

7. Cosa ha senso monitorare da qui in avanti

Tolto il rumore di breve, i punti davvero importanti per capire se la storia JFBR / KeepZone fa un salto di qualità sono pochi ma chiari:

  • un PR che passi da “accordo di distribuzione” a “contratto firmato dal valore di X su Y anni”, meglio ancora se con uno dei clienti governativi citati;
  • documenti (8-K, presentazioni) che inizino a isolare i ricavi e i margini di KeepZone rispetto al core Amazon;
  • maggiore chiarezza su come il business retail verrà gestito nel tempo: tenuto e ottimizzato, venduto, ridimensionato?

In sintesi: per chi segue le storie run-up è un nome da tenere sul radar perché il newsflow c’è ed è coerente, ma il vero salto di qualità passa da numeri misurabili nei contratti e nei filing, non solo da nuove partnership annunciate a catena.

Fonti principali e dati

  • GlobeNewswire – accordo di distribuzione KeepZone AI x STI (16 gennaio 2026) Comunicato ufficiale
  • Altri accordi KeepZone AI (Scanary, RT LTA, ecc.) Flusso news JFBR su Finviz
  • Dati di prezzo e fondamentali (ricavi 2024, utile netto, market cap, last price, range 52 settimane) Yahoo Finance · Nasdaq · Investing.com · TradingView · Finviz quote
  • Copertura analisti (assenza di target recenti) Pagina price target JFBR su Zacks
Nota legale / educativa. Questo Daily Hit ha scopo puramente informativo ed educativo, basato su comunicati ufficiali, dati di bilancio e provider di market data riconosciuti. Non costituisce in alcun modo raccomandazione di investimento, né sollecitazione al pubblico risparmio. Titoli micro-cap come JFBR possono essere estremamente volatili e illiquidi; prima di qualsiasi decisione operativa è indispensabile verificare i documenti originali (SEC, report certificati, comunicati integrali) e, se necessario, confrontarsi con un consulente finanziario abilitato.

What do you feel about this?

  • Intraday
  • Small Caps Trending

Post navigation

Previous: OCUL Ocular Therapeutix Inc
Next: ASND Ascendis Pharma

Related Stories

HYLN
  • Small Caps Trending

Hyliion Holdings Corp. (NYSE American: $HYLN): The KARNO Pivot, Navy Validation, Data Center Optionality and the Real Execution Test Ahead

1
Investimenti biotech small/mid cap con acquisti insider nel 2026.
  • Small Caps Trending

The 3 Biggest Insider Buys of May 2026:$KLRA, $ODTX and $ARTV

0
  • Intraday

Actelis Networks ( $ASNS ) – Cyber-Hardened Networking For Critical Infrastructure In 2026

2
  • Small Caps Trending

US Energy Corp ( $USEG )

4
  • Weekly Reports
  • Defence
  • Medium Caps Trending
  • Small Caps Trending

WAR US–Israel vs Iran, 2026 Small & mid-cap potential “winners & losers”

2
  • AI
  • BBAI
  • Defence
  • Small Caps Trending

BigBear.ai Holdings Inc ( $BBAI )

0

Trending Now

Fed, Inflation and Oil: Why SPY Is Trading the Energy Shock Before the June FOMC Spy oil inflation 1
  • Editorial

Fed, Inflation and Oil: Why SPY Is Trading the Energy Shock Before the June FOMC

15
The Truce That Changes the Tape: the U.S.-Iran Deal Reopens the Hormuz Question truce Usa Iran 2
  • Editorial

The Truce That Changes the Tape: the U.S.-Iran Deal Reopens the Hormuz Question

53
Celldex Therapeutics — Barzolvolimab, Mast Cells and the Revolution in Chronic Urticaria Treatmen cldx 3
  • Reports Biotech

Celldex Therapeutics — Barzolvolimab, Mast Cells and the Revolution in Chronic Urticaria Treatmen

75
Neumora Therapeutics (Nasdaq: $NMRA): Navacaprant Is Over, the Platform Story Moves to NMRA-511, NMRA-898 and NMRA-215 nmra 4
  • Reports Biotech

Neumora Therapeutics (Nasdaq: $NMRA): Navacaprant Is Over, the Platform Story Moves to NMRA-511, NMRA-898 and NMRA-215

70

Welcome to Merlintrader!
Here we share ideas, analysis and news from the biotech and small-cap world, with a special focus on the catalysts that really move the market.
If you like the content on this site, please help me by sharing it on social media and in other forums. Thank you!

✦ Disclaimer: The information provided is strictly for educational and informational purposes. This content represents independent, informational research and does not constitute regulated investment research or financial advice. I am not a licensed financial advisor or an authorized investment professional. Nothing here should be interpreted as a recommendation to buy, sell, or trade any security. If you need personalized financial advice, you should consult a qualified and authorized professional. Biotech and small-cap stocks carry significant risk, including the potential loss of all invested capital. Each user remains fully responsible for their own trading decisions. Full legal disclaimers.
✦ RunUP Biotech: Interested in understanding market dynamics around FDA catalysts and clinical trials? The RunUP Biotech strategy provides a framework for analyzing pre-event positioning, volume patterns, and risk-management approaches. Educational focus on probability and pattern structure — not predictions or guaranteed outcomes. Learn more →
✦ Support Merlintrader: This website is free and has no paywall. If you find the reports and tools useful, you can support the project via Buy Me a Coffee — it helps me cover costs and keep publishing independent analysis.
✦ Disclosure: I closed my DRTS position today, May 11, at $10.29 per share, after entering at $7.31 per share. I opened a small position in CING on May 12 at $4.90 per share. Read the full disclaimer.
```
Free research library

Explore the Merlintrader blog

Inside the site you will find hundreds of free reports, deep dives on biotech and small caps, FDA catalyst coverage, market analysis, and articles built to help readers understand what really moves these stocks.

  • Full reports on individual stocks
  • FDA, catalyst and clinical-trial analysis
  • Daily briefings, watchlists and market themes
  • A free archive updated on a regular basis
Explore the blog

Free content, readable structure, and regular updates.

Archivio gratuito

Esplora il blog Merlintrader

Nel sito trovi centinaia di report gratuiti, approfondimenti su biotech e small cap, catalyst FDA, analisi di mercato e articoli pensati per aiutare i lettori a capire meglio cosa muove davvero questi titoli.

  • Report completi su singoli titoli
  • Analisi di catalyst, FDA e trial clinici
  • Daily briefing, watchlist e temi di mercato
  • Un archivio gratuito aggiornato con regolarità
Vai al blog

Contenuti gratuiti, struttura leggibile e aggiornamenti costanti.

Merlintrader Newsletter

Stay ahead of the next catalyst

Get market notes, deep-dive updates and catalyst-focused research directly from Merlintrader.

Educational market content only. No spam. You can unsubscribe anytime.
Terms, privacy and disclaimer
DISCLAIMER — Educational content only. Not financial advice. Stocks can be volatile and may cause capital loss.
Read Disclaimer
Scanner for active traders
ChartsWatcher logo

Try ChartsWatcher free, then unlock 10% OFF with SAVE10

ChartsWatcher is a real-time scanner for momentum traders: fast movers, unusual volume and rotations — so you can focus on the few tickers that matter right now, instead of watching hundreds of charts.

Start with the free version. When you upgrade, use SAVE10 for 10% OFF your first paid period.

Start free – then use SAVE10

No credit card required to start. Apply SAVE10 when upgrading.

ChartsWatcher platform screenshot
Recommended platform
Medved Trader logo

One platform. All your brokers.

Medved Trader connects multiple brokers in one workspace, with pro charts, hotkeys and fast execution — without changing your broker accounts.

A single cockpit for positions, Level II and multi-broker order routing, built for active day & swing traders.

Get 1 Month Free ➔

Multi-broker workflow + customizable layouts in one platform.

Medved Trader platform dashboard
Merlintrader author

Authors: Merlintrader, Jane and Gemini

Author's note

In every piece of content I share things as I personally interpret them, based on raw data from official company filings, regulatory documents, conference call transcripts and other primary sources where available. Some parts of the research and structure are supported by AI assistants (Jane and Gemini), which help me organise data, cross-check details and improve charts or visuals. However, any interpretation, opinion and final judgement remain entirely my own as a trader like you, not as a licensed financial advisor or registered analyst. Market sentiment can change quickly, while official documents and numbers remain what they are. It is also possible for me to make mistakes: collecting and cross-checking FDA timelines, clinical data, filings and corporate updates is complex, so inaccuracies may occur. If you spot something that looks off, feel free to let me know and I will correct it. Please do not treat this content as professional investment advice, but as one more piece of information to compare with your own research and the opinion of qualified professionals.

Donate via PayPal

If you find these reports useful and want to support the project, you can make a voluntary one-time donation via PayPal or Buy Me a Coffee. It helps cover data, tools and hosting costs so that the content can remain independent and freely accessible.

Buy Me a Coffee

Tools and research platforms used by Merlintrader

Below is a shortlist of tools and platforms that I personally use to follow prices, catalysts, fundamentals and sentiment. Links are provided for transparency and convenience only.

  • Finviz Elite – advanced stock screener and charting, used for heatmaps, relative performance and technical context.
  • ChartsWatcher – real-time, next-generation scanner for the US stock market. Used to monitor intraday momentum, volume spikes and colour-coded pattern alerts.
  • Stocktwits – social stream focused on tickers, used only as a sentiment and activity indicator, not as a source of investment recommendations.
  • Monica.im – AI assistant used for light reports, drafting and quick research; helps with structuring notes and first-pass analysis alongside the deep-dive work published on Merlintrader.
  • Medved Trader – professional trading and charting platform used for real-time execution, order-flow and detailed intraday analysis. No affiliate link; mentioned because it is part of the actual trading workflow.
  • Merlintrader trading Blog – the home for biotech-focused reports, dashboards and educational articles that expand on the ideas mentioned in this document.

AI usage disclosure

Content on Merlintrader may be prepared using a human + AI workflow. Drafting, editing and data organisation may be supported by generative AI tools, for example large language models provided by third-party vendors, based on prompts and instructions defined by the author. All sources are publicly available, and the final selection of data, checks, opinions and conclusions is carried out by the author, who remains fully responsible for the content.

Monica.im Monica.im – the AI assistant I use every day
If you find value in the work I publish on Merlintrader and want a practical AI assistant for research and writing, you can sign up using this referral link. Click here to try Monica.im and support the site

Find out how I use AI on Merlintrader: AI, retail and Merlintrader

Disclosure: some of the links in the promotional blocks above are affiliate or referral links. If you choose to subscribe or sign up through them, Merlintrader may receive a small commission or benefit at no extra cost to you.

Legal disclaimer – please read carefully

Each piece of content is provided strictly for informational and educational purposes. It is not and must not be interpreted as investment advice, investment research in a regulatory sense, portfolio management, or a recommendation to buy or sell any security or financial instrument. The author is not a licensed investment advisor, not a registered broker, and not a FINRA/SEC-registered analyst or portfolio manager. Any reference to potential scenarios, price levels or catalysts is purely illustrative and reflects a personal, non-professional view based on publicly available information at the time of writing.

Nothing in any content published on Merlintrader should be considered a solicitation to the public to invest, nor an invitation to raise capital, nor a promise of profit or of capital protection. Biotech and healthcare stocks in particular can be highly volatile and speculative, especially around clinical and regulatory catalysts. Before making any investment or trading decision, always perform your own due diligence and consider consulting a qualified, regulated financial professional who can evaluate your personal situation, objectives and risk tolerance. Past performance and historical examples do not guarantee future results.

The author may hold, or may have held, long or short positions in some of the securities mentioned in Merlintrader content, and may open, close or modify such positions without notice. This potential alignment of interests may influence the tone or focus of the analysis. No position held by the author changes the fact that this content is not investment advice and should not be used as such.

Biotech Catalyst Calendar

For a broader, continuously updated view of upcoming biotech catalysts (PDUFA dates, major clinical readouts, regulatory events and key conferences), you can consult the dedicated calendar on Merlintrader.

Open the Biotech Catalyst Calendar

  • Voce di menu
  • Voce di menu
  • Voce di menu
  • Voce di menu
  • Our Profile on PRLog
Terms and Conditions
Cookie Policy
Privacy Policy
Merlintrader is a personal blog curated by Horacio F. Greco. Contact: info@merlintrader.com. No professional financial advice.
Do Not Sell or Share My Personal Information